XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Collaboration Agreements - Summary of Collaboration Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative revenue, revenue from contract with customer [1] $ 294,123 $ 52,480 $ 329,264 $ 94,621
Total Collaboration Revenue 294,123 52,480 329,264 94,621
Takeda Collaboration Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total Collaboration Revenue 0 12,000 10,000 51,916
Revenue recognized included in the contract liability balance at the beginning of the period   0   27,900
Takeda Collaboration Agreement | Collaboration Agreement Services        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative revenue, revenue from contract with customer 0 12,000 0 51,916
Takeda Collaboration Agreement | PTV:PGRN Collaboration Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative revenue, revenue from contract with customer 0 0 10,000 0
Sanofi Collaboration Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total Collaboration Revenue 0 40,000 25,000 40,000
Sanofi Collaboration Agreement | CNS Program License        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative revenue, revenue from contract with customer 0 40,000 25,000 40,000
Biogen        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total Collaboration Revenue 294,123 480 294,264 2,705
Biogen | ATV:Abeta Program License        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative revenue, revenue from contract with customer 293,912 0 293,912 0
Biogen | Option Research Services        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative revenue, revenue from contract with customer 211 $ 480 352 $ 2,705
Collaborative Arrangement, ATV:Abeta        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue recognized included in the contract liability balance at the beginning of the period $ 288,900   $ 288,900  
[1] Includes related-party collaboration revenue from customers of $294.1 million and $294.3 million for the three and six months ended June 30, 2023, respectively, and $0.5 million and $2.7 million for the three and six months ended June 30, 2022, respectively.